title: NMS and genetic drug oxidation.
authors.forename: K
authors.initials: K
authors.lastname: Otani
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.forename: Y
authors.initials: Y
authors.lastname: Fukushima
authors.forename: K
authors.initials: K
authors.lastname: Chiba
authors.forename: T
authors.initials: T
authors.lastname: Ishizaki
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006220:Haloperidol / Q000009:adverse effects / Q000493:pharmacokinetics*; D006801:Humans; D008658:Inactivation, Metabolic / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000097:blood / Q000235:genetics*; D010546:Perphenazine / Q000009:adverse effects / Q000493:pharmacokinetics*; D010641:Phenotype; D012307:Risk Factors
chemical_list: D010546:Perphenazine; D006220:Haloperidol